298 related articles for article (PubMed ID: 37480884)
1. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
[TBL] [Abstract][Full Text] [Related]
2. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Lichtenstein DA; Schischlik F; Shao L; Steinberg SM; Yates B; Wang HW; Wang Y; Inglefield J; Dulau-Florea A; Ceppi F; Hermida LC; Stringaris K; Dunham K; Homan P; Jailwala P; Mirazee J; Robinson W; Chisholm KM; Yuan C; Stetler-Stevenson M; Ombrello AK; Jin J; Fry TJ; Taylor N; Highfill SL; Jin P; Gardner RA; Shalabi H; Ruppin E; Stroncek DF; Shah NN
Blood; 2021 Dec; 138(24):2469-2484. PubMed ID: 34525183
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Zu C; Wang K; Zhang Q; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):160-166. PubMed ID: 36161295
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.
Hines MR; Keenan C; Maron Alfaro G; Cheng C; Zhou Y; Sharma A; Hurley C; Nichols KE; Gottschalk S; Triplett BM; Talleur AC
Br J Haematol; 2021 Aug; 194(4):701-707. PubMed ID: 34263927
[TBL] [Abstract][Full Text] [Related]
5. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hines MR; Knight TE; McNerney KO; Leick MB; Jain T; Ahmed S; Frigault MJ; Hill JA; Jain MD; Johnson WT; Lin Y; Mahadeo KM; Maron GM; Marsh RA; Neelapu SS; Nikiforow S; Ombrello AK; Shah NN; Talleur AC; Turicek D; Vatsayan A; Wong SW; Maus MV; Komanduri KV; Berliner N; Henter JI; Perales MA; Frey NV; Teachey DT; Frank MJ; Shah NN
Transplant Cell Ther; 2023 Jul; 29(7):438.e1-438.e16. PubMed ID: 36906275
[TBL] [Abstract][Full Text] [Related]
6. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
Kim DW; Bukhari A; Lutfi F; Zafforoni F; Merechi F; Mustafa Ali MK; Gottlieb D; Lee ST; Kocoglu MH; Hardy NM; Yared J; Rapoport AP; Dahiya S; Law JY
Leuk Lymphoma; 2022 Jun; 63(6):1339-1347. PubMed ID: 35045791
[TBL] [Abstract][Full Text] [Related]
7. Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.
Hoyt R; Ye Z; Dasgupta A
Clin Chim Acta; 2024 Jun; 559():119704. PubMed ID: 38697457
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
Diorio C; Shraim R; Myers R; Behrens EM; Canna S; Bassiri H; Aplenc R; Burudpakdee C; Chen F; DiNofia AM; Gill S; Gonzalez V; Lambert MP; Leahy AB; Levine BL; Lindell RB; Maude SL; Melenhorst JJ; Newman H; Perazzelli J; Seif AE; Lacey SF; June CH; Barrett DM; Grupp SA; Teachey DT
Clin Cancer Res; 2022 Sep; 28(17):3804-3813. PubMed ID: 35705524
[TBL] [Abstract][Full Text] [Related]
9. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Major A; Collins J; Craney C; Heitman AK; Bauer E; Zerante E; Stock W; Bishop MR; Jasielec J
Leuk Lymphoma; 2021 Jul; 62(7):1765-1769. PubMed ID: 33559517
[No Abstract] [Full Text] [Related]
10. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
[TBL] [Abstract][Full Text] [Related]
11. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
Yang C; Nguyen J; Yen Y
J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
[TBL] [Abstract][Full Text] [Related]
12. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
15. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study.
Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I
Front Immunol; 2023; 14():1219289. PubMed ID: 37600775
[TBL] [Abstract][Full Text] [Related]
16. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
17. Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.
Masih KE; Ligon JA; Yates B; Shalabi H; Little L; Islam Z; Ombrello AK; Inglefield J; Nussenblatt V; Manion M; Khan J; Shah NN
Pediatr Blood Cancer; 2021 Oct; 68(10):e29247. PubMed ID: 34309174
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).
Sandler RD; Tattersall RS; Schoemans H; Greco R; Badoglio M; Labopin M; Alexander T; Kirgizov K; Rovira M; Saif M; Saccardi R; Delgado J; Peric Z; Koenecke C; Penack O; Basak G; Snowden JA
Front Immunol; 2020; 11():524. PubMed ID: 32296434
[No Abstract] [Full Text] [Related]
19. Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K; Subklewe M; Locke FL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
[TBL] [Abstract][Full Text] [Related]
20. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
